Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Common Equity: 2015-2024

Historic Common Equity for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $13.8 million.

  • Seres Therapeutics' Common Equity rose 82.69% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.7 million, marking a year-over-year increase of 82.69%. This contributed to the annual value of $13.8 million for FY2024, which is 130.73% up from last year.
  • Per Seres Therapeutics' latest filing, its Common Equity stood at $13.8 million for FY2024, which was up 130.73% from -$44.9 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Common Equity ranged from a high of $174.8 million in FY2020 and a low of -$44.9 million during FY2023.
  • In the last 3 years, Seres Therapeutics' Common Equity had a median value of $10.8 million in 2022 and averaged -$6.8 million.
  • Per our database at Business Quant, Seres Therapeutics' Common Equity skyrocketed by 461.62% in 2020 and then slumped by 515.99% in 2023.
  • Over the past 5 years, Seres Therapeutics' Common Equity (Yearly) stood at $174.8 million in 2020, then fell by 24.75% to $131.5 million in 2021, then slumped by 91.80% to $10.8 million in 2022, then slumped by 515.99% to -$44.9 million in 2023, then surged by 130.73% to $13.8 million in 2024.